ATE261126T1 - Verfahren für lösung-basierte diagnose - Google Patents

Verfahren für lösung-basierte diagnose

Info

Publication number
ATE261126T1
ATE261126T1 AT02017313T AT02017313T ATE261126T1 AT E261126 T1 ATE261126 T1 AT E261126T1 AT 02017313 T AT02017313 T AT 02017313T AT 02017313 T AT02017313 T AT 02017313T AT E261126 T1 ATE261126 T1 AT E261126T1
Authority
AT
Austria
Prior art keywords
diagnosis
solution
medically relevant
markers
substitute
Prior art date
Application number
AT02017313T
Other languages
English (en)
Inventor
Ruediger Ridder
Wolfgang Rudy
Matthias Herkert
Marcus Trunk-Gehmacher
Anja Reichert
Knebel Doeberitz Magnus Von
Original Assignee
Mtm Lab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mtm Lab Ag filed Critical Mtm Lab Ag
Application granted granted Critical
Publication of ATE261126T1 publication Critical patent/ATE261126T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
AT02017313T 2002-08-01 2002-08-01 Verfahren für lösung-basierte diagnose ATE261126T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02017313A EP1388734B1 (de) 2002-08-01 2002-08-01 Verfahren für Lösung-basierte Diagnose

Publications (1)

Publication Number Publication Date
ATE261126T1 true ATE261126T1 (de) 2004-03-15

Family

ID=30129176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02017313T ATE261126T1 (de) 2002-08-01 2002-08-01 Verfahren für lösung-basierte diagnose

Country Status (13)

Country Link
US (3) US7517662B2 (de)
EP (2) EP1388734B1 (de)
JP (4) JP2005534313A (de)
CN (1) CN100570366C (de)
AT (1) ATE261126T1 (de)
AU (1) AU2003262554B2 (de)
CA (1) CA2487048C (de)
DE (1) DE60200248T2 (de)
DK (1) DK1388734T3 (de)
ES (1) ES2215957T3 (de)
MX (1) MXPA04012648A (de)
RU (1) RU2315312C2 (de)
WO (1) WO2004013632A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
EP1369694A1 (de) 2002-04-09 2003-12-10 MTM Laboratories AG Verfahren zur Unterscheidung zwischen Metaplasien und neoplastischen oder präneoplastischen Läsionen
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
DE60200248T2 (de) 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
EP1422526A1 (de) 2002-10-28 2004-05-26 MTM Laboratories AG Verfahren zur verbesserten Diagnose von Dysplasien
EP1510820B1 (de) * 2003-08-25 2010-03-17 MTM Laboratories AG Verfahren zum Nachweis von medizinisch relevanten Zuständen in gelösten LBC-Proben
ATE289685T1 (de) 2003-08-25 2005-03-15 Mtm Lab Ag Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
US7402399B2 (en) * 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
JP4912894B2 (ja) 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
US7229778B2 (en) * 2004-02-26 2007-06-12 The Procter & Gamble Company Methods for determining the relative benefits and/or evaluating quantitative changes of products on epithelial tissue
DE102004009934A1 (de) * 2004-02-26 2005-09-22 Niendorf, Axel, Prof.Dr.med. Verfahren zur Untersuchung einer Gewebeprobe
ES2381644T3 (es) 2004-03-24 2012-05-30 Tripath Imaging, Inc. Métodos y composiciones para la detección de enfermedades de cuello uterino
DE602005024964D1 (de) * 2004-05-31 2011-01-05 Sysmex Corp Verfahren zur beurteilung der malignität einer säuger-krebszelle
GB0413001D0 (en) 2004-06-10 2004-07-14 Johnson & Johnson Medical Ltd Diagnostic and prognostic
EP1628135A1 (de) * 2004-08-20 2006-02-22 MTM Laboratories AG Verfahren zum Nachweis von medizinisch relevanten Zuständen in gelösten LBC Proben
ITBO20040576A1 (it) * 2004-09-17 2004-12-17 Alma Mater Studiorum Uni Di Bologna Metodo e kit per la valutazione della frammentazione di dna a seguito di esposizione a radiazione
EP1802978B1 (de) * 2004-10-14 2011-11-23 Genentech, Inc. Cop1-moleküle und verwendungen davon
EP1839056B1 (de) * 2004-12-21 2011-08-03 Yale University Präeklampsie-diagnose
US7595380B2 (en) * 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2007013949A2 (en) * 2005-07-21 2007-02-01 Wayne State University Asbestos exposure, pleural mesothelioma, and serum osteopontin levels
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
US8220704B2 (en) * 2006-01-24 2012-07-17 Mycrolab Diagnostics Pty Ltd Methods for low cost manufacturing of complex layered materials and device
EP1816460B1 (de) 2006-02-03 2009-07-22 MTM Laboratories AG Verfahren zur Durchführung eines Denaturierungs-Immunoassays
WO2007103770A2 (en) * 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
RU2310197C1 (ru) * 2006-03-17 2007-11-10 ФГУ Ростовский НИИ акушерства и педиатрии Росздрава Способ прогнозирования предраковых заболеваний шейки матки у женщин с папиллома-вирусной инфекцией
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
EP2041299A4 (de) 2006-07-14 2010-01-13 Aviva Biosciences Corp Verfahren und zusammensetzungen für den nachweis seltener zellen aus einer biologischen probe
US8043822B2 (en) * 2006-11-02 2011-10-25 Kyowa Medex Co., Ltd. Method of immunoassaying a component to be measured
US8278056B2 (en) 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
WO2010129821A1 (en) * 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
US8877507B2 (en) * 2007-04-06 2014-11-04 Qiagen Gaithersburg, Inc. Ensuring sample adequacy using turbidity light scattering techniques
RU2369873C1 (ru) * 2008-03-18 2009-10-10 Государственное образовательное учреждение высшего профессионального образования Читинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию Способ подготовки пробы биологического материала для иммуноферментного анализа
RU2372405C1 (ru) * 2008-08-04 2009-11-10 Павел Петрович Лактионов Способ выделения внеклеточных дезоксирибонуклеиновых кислот из крови
EP2356460B1 (de) * 2008-09-04 2018-01-24 Ventana Medical Systems, Inc. Verfahren zur vorhersage der gefahr des fortschreitens von tumoren
WO2010045318A2 (en) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
EP2224244A1 (de) * 2009-02-26 2010-09-01 Universität des Saarlandes In-vitro-Diagnoseverfahren oder Assay zur Diagnose der chronischen obstruktiven Lungenerkrankung
RU2426991C2 (ru) * 2009-05-25 2011-08-20 Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) Способ прогнозирования исходов плоскоклеточных опухолей головы и шеи
EP2270510A1 (de) * 2009-07-02 2011-01-05 EMBL (European Molecular Biology Laboratory) Diagnoseverfahren zur Vorhersage des Krebsrekurrenzrisikos basierend auf Histon-macroH2A-Isoformen
CN101942017B (zh) * 2009-07-07 2013-08-14 清华大学 一种新的肿瘤标志物
EP2333105A1 (de) * 2009-12-08 2011-06-15 Koninklijke Philips Electronics N.V. Selektive Lyse von Zellen
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
EP3040425B1 (de) 2010-02-17 2019-08-28 Gen-Probe Incorporated Zusammensetzungen und verfahren für den nachweis von atopobium vaginae-nukleinsäure
EP2542696B1 (de) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Theranostik-biomarker
WO2011109705A2 (en) * 2010-03-04 2011-09-09 Purdue Research Foundation Integrated assay that combines flow-cytometry and multiplexed hpv genotype identification
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
RU2464570C2 (ru) * 2010-11-19 2012-10-20 Федеральное государственное учреждение "Российский научный центр рентгенрадиологии" Министерства здравоохранения и социального развития России Метод диагностики цервикальных интраэпителиальных неоплазий
WO2012149034A1 (en) 2011-04-25 2012-11-01 Gen-Probe Incorporated Compositions and methods for detecting bv-associated bacterial nucleic acid
CN107034132B (zh) * 2011-05-05 2025-11-14 宁卡赛科技(上海)有限公司 肿瘤细胞检测仪
EP2726868B1 (de) 2011-06-30 2015-11-04 GE Healthcare Bio-Sciences AB Zellbindungsassay
WO2013016449A2 (en) * 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
WO2013036928A1 (en) 2011-09-08 2013-03-14 Gen-Probe Incorporated Compositions and methods for detecting bv-associated bacterial nucleic acid
EP2773390B1 (de) 2011-11-03 2020-12-30 Tripath Imaging, Inc. Verfahren und zusammensetzungen zur vorbereitung von proben auf die immunoeinfärbung
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
RU2508542C1 (ru) * 2012-07-16 2014-02-27 Полина Михайловна Шварцбурд Экспресс-способ определения риска злокачественности клеток
EP2895623B1 (de) 2012-09-17 2018-08-22 Agios Pharmaceuticals, Inc. Verwendung von e-cadherin und vimentin zur auswahl von auf eine behandlung ansprechenden patienten
AU2013205122B2 (en) 2012-10-11 2016-11-10 Gen-Probe Incorporated Compositions and Methods for Detecting Human Papillomavirus Nucleic Acid
MX369691B (es) 2012-11-21 2019-11-19 Agios Pharmaceuticals Inc Inhibidores de glutaminasa y métodos de empleo.
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
RU2538618C2 (ru) * 2012-12-26 2015-01-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Петрозаводский государственный университет" Способ дифференциальной диагностики цервикальных дисплазий и рака шейки матки
BR112015023120A2 (pt) * 2013-03-15 2017-11-21 Genentech Inc método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
RU2535042C1 (ru) * 2013-11-25 2014-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ определения биологического возраста трупа при длительной кровопотере
BR112016021620A2 (pt) 2014-03-21 2018-07-10 Agios Pharmaceuticals Inc compostos e seus métodos de uso
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
KR101858801B1 (ko) * 2015-01-30 2018-05-17 중앙대학교 산학협력단 혈중 항체의 당질분석을 통한 자궁경부암의 진단방법 및 이를 이용한 진단키트
JP6854246B2 (ja) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド 尿サンプルの分析方法
EP3304084B1 (de) 2015-06-08 2022-03-23 Arquer Diagnostics Limited Verfahren und kits
CN108267586A (zh) * 2016-12-30 2018-07-10 苏州和锐生物科技有限公司 一种人ck18蛋白检测试剂及其制备方法
KR102502745B1 (ko) * 2017-06-29 2023-02-23 옌타이 콴티시젼 다이애그노틱스 인크. 고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치
JP7432610B2 (ja) 2018-10-01 2024-02-16 ジェン－プローブ・インコーポレーテッド 水痘帯状疱疹ウイルスを増幅または検出するための組成物および方法
CN111257565A (zh) * 2018-12-03 2020-06-09 上海细胞治疗集团有限公司 一种衰老细胞的检测试剂盒及其检测方法
CN109781977B (zh) * 2019-01-09 2022-03-29 首都医科大学附属北京安定医院 IL15Rα以及相关膜蛋白检测试剂盒及其应用
CN110672558B (zh) * 2019-09-24 2022-05-10 东南大学 基于oct技术的神经活动观测方法及系统
CN113702341B (zh) * 2020-05-22 2022-08-16 中国科学院大连化学物理研究所 一种过氧化物酶催化的细胞表面蛋白质标记方法
US20240295561A1 (en) * 2021-06-17 2024-09-05 Konica Minolta, Inc. Quantification method and labeling method
CN113985028A (zh) * 2021-11-25 2022-01-28 济南百博生物技术股份有限公司 一种用于胶体金法抗原检测稀释液
CN115389598A (zh) * 2022-09-27 2022-11-25 达碧清诊断技术(上海)有限公司 糖化血红蛋白的快速聚焦电泳定量分析方法
CN120085011A (zh) * 2025-01-17 2025-06-03 中国人民解放军总医院第三医学中心 用于检测膀胱损伤的组合物和检测试纸

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US39023A (en) * 1863-06-23 Improvement in churns
US86288A (en) * 1869-01-26 Improvement in bbeb-drill and corn-covereh
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
DE3923951A1 (de) 1989-07-19 1991-01-31 Boehringer Mannheim Gmbh Verfahren zum nachweis von leberzirrhose
JPH0580053A (ja) * 1991-03-22 1993-03-30 Shiro Nozawa ヒト子宮体癌細胞の免疫化学的検出方法
US5776783A (en) * 1993-11-02 1998-07-07 Private Clinic Laboratories, Inc. Method of monitoring therapeutic agent consumption
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
CA2164167A1 (en) * 1994-12-20 1996-06-21 Izak Bahar Assay normalization method
US6033847A (en) * 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
GB9519275D0 (en) * 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US5976799A (en) * 1996-03-21 1999-11-02 The Board Of Trustees Of The University Of Arkansas Early detection of ovarian carcinoma using P16 gene products
GB9616429D0 (en) 1996-08-05 1996-09-25 Quantum Biosystems Ltd Assessment of cervical cells
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
EP0969868A2 (de) * 1997-03-18 2000-01-12 Ortho-Mcneil Pharmaceutical, Inc. Verfahren und kits zur behandlung und diagnose von leiomyome
AU8403098A (en) * 1997-07-15 1999-02-10 Deaconess Hospital Reagents and methods for diagnosis and prognosis of proliferative disor ders
EP1057036A1 (de) * 1998-02-25 2000-12-06 New York Medical College Durchflusscytometrischer nachweis von konformationen von prb in einzelzellen
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US6593084B2 (en) 1998-10-13 2003-07-15 Robert E. Bird Carcinogen assay
US6331393B1 (en) * 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6864066B1 (en) * 1999-09-08 2005-03-08 The Regents Of The University Of California Epithelial protein lost in neoplasm (EPLIN)
CA2388517A1 (en) 1999-11-16 2001-05-25 The General Hospital Corporation Compositions and methods for regulating tumor-associated antigen expression
WO2001038878A2 (en) 1999-11-29 2001-05-31 Beth Israel Deaconess Medical Center Pin1 as a marker for abnormal cell growth
DE10014685B4 (de) 2000-03-24 2004-07-01 Schubert, Walter, Dr. Verfahren zur Identifizierung von zellspezifischen Zielstrukturen
EP1325338A2 (de) * 2000-04-03 2003-07-09 Oxford GlycoSciences (UK) Limited Diagnose und behandlung der alzheimerschen krankheit
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
AUPQ901700A0 (en) * 2000-07-26 2000-08-17 National Cancer Centre Of Singapore Pte Ltd Molecular markers
EP1320551A4 (de) * 2000-09-01 2006-12-20 Internat Bioimmune Systems Inc Identifikation und entwicklung von spezifischen monoklonalen antikörpern gegen plattenepithelkarzinom
US6548252B1 (en) * 2000-10-13 2003-04-15 Esa, Inc. Detection of DNA damage
DE10063179A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
EP1369694A1 (de) 2002-04-09 2003-12-10 MTM Laboratories AG Verfahren zur Unterscheidung zwischen Metaplasien und neoplastischen oder präneoplastischen Läsionen
DE60200248T2 (de) 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
EP1422526A1 (de) 2002-10-28 2004-05-26 MTM Laboratories AG Verfahren zur verbesserten Diagnose von Dysplasien
EP2356460B1 (de) 2008-09-04 2018-01-24 Ventana Medical Systems, Inc. Verfahren zur vorhersage der gefahr des fortschreitens von tumoren

Also Published As

Publication number Publication date
US20090181406A1 (en) 2009-07-16
DK1388734T3 (da) 2004-05-03
JP5997094B2 (ja) 2016-09-28
EP1388734B1 (de) 2004-03-03
CN1675550A (zh) 2005-09-28
US7517662B2 (en) 2009-04-14
RU2315312C2 (ru) 2008-01-20
DE60200248T2 (de) 2005-01-27
JP2013210373A (ja) 2013-10-10
US20150065383A1 (en) 2015-03-05
US20040023288A1 (en) 2004-02-05
DE60200248D1 (de) 2004-04-22
US10697966B2 (en) 2020-06-30
MXPA04012648A (es) 2005-03-23
JP2015180201A (ja) 2015-10-15
EP1525476A1 (de) 2005-04-27
CN100570366C (zh) 2009-12-16
JP2010266460A (ja) 2010-11-25
EP1388734A1 (de) 2004-02-11
CA2487048C (en) 2010-08-17
WO2004013632A1 (en) 2004-02-12
AU2003262554A1 (en) 2004-02-23
JP2005534313A (ja) 2005-11-17
CA2487048A1 (en) 2004-02-12
AU2003262554B2 (en) 2009-02-19
RU2005101643A (ru) 2005-06-27
ES2215957T3 (es) 2004-10-16

Similar Documents

Publication Publication Date Title
ATE261126T1 (de) Verfahren für lösung-basierte diagnose
Bilous et al. Current perspectives on HER2 testing: a review of national testing guidelines
CN112735533B (zh) 一种基于eDNA的水生生态分析方法及系统
US20220389523A1 (en) Image acquisition methods for simultaneously detecting genetic rearrangement and nuclear morphology
CA2573732A1 (en) Automated system of processing biological specimens and method
RU2004135411A (ru) Цепь сохранности флюидов
Kuroda et al. Novel sperm chromatin dispersion test with artificial intelligence‐aided halo evaluation: a comparison study with existing modalities
ATE437365T1 (de) Probentestträger und verfahren zur prüfung von okkultem blut im stuhl
US8969031B2 (en) Automated cell density adjustment method for producing an analysis plate
BRPI0901542A2 (pt) dispositivo leitor de microtubo para a análise de amostras de sangue
Singh et al. Protein Biomarkers: Discovery and Applications in Clinical Diagnostics
Park et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer
Komori et al. Comparative study of sperm motility analysis system and conventional microscopic semen analysis
Innaro et al. Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell‐based cytology
JP2010117290A (ja) 液体試料成分の分析装置および分析方法
Skandan et al. Using latent class analysis to examine polysubstance use patterns in adolescents aged 10-18: A systematic review
WO2022271865A9 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
KR101477421B1 (ko) 차량 부품 도막 노화도 평가방법
ATE418725T1 (de) Verfahren zur verifikation der verwendung eines bestimmten färbemittels für eine zellprobe
Kurdi Neuromuscular Pathology Made Easy
KR102907991B1 (ko) 광학 기술을 이용한 기생충란 검출 방법 및 장치
Knox et al. Objective interpretation of bovine clinical biochemistry data: application of Bayes law to a database model
Jacobsen et al. Optimisation of Haematoxylin and Eosin staining in a diagnostic hospital laboratory.
US20220106635A1 (en) Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
Gu Developing Spatialomics Platforms to Profile Biomarkers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties